Komposition, Choreograhpie und Orchestrierung von Web Services: Ein Überblick

Der Bedarf von Unternehmen nach einer system- und bereichsübergreifenden Anwendungsintegration ist hoch. Die mittlerweile verfügbaren Standards für Web Services (UDDI, WSDL, SOAP) bieten einen viel versprechenden Ansatz für den Aufbau integrierter, serviceorientierter Architekturen. Sie sind offen, einfach und plattformunabhängig. Allerdings stellt die prozessorientierte Verknüpfung heterogener Anwendungs bausteine eine komplexe Aufgabe dar, und es ist noch nicht wirklich absehbar, wie sich die Vielfalt der Empfehlungen, Standards und Werkzeuge entwickeln wird. Vision ist die automatische Auswahl und prozessorientierte Komposition von Web Services. Für die dazu notwendige semantische Beschreibung der Dienste gibt es jedoch noch keine allgemein akzeptierten Konventionen. Ebenso befinden sich andere Aspekte wie Sicherheit und Verlässlichkeit noch in der Entwicklung. Dieser Artikel gibt eine Einführung in Web Services und behandelt Aspek te der Komposition, Choreographie und Orchestrierung von Web Services. Zudem wird auf sich abzeichnende bzw. aufkommende Standards eingegangen

Entwicklung eines standardisierten Erhebungsinstrumentariums für die Kleinbetriebsforschung in Entwicklungsländern: ein Arbeitsbericht

Die Autoren sind wissenschaftliche Mitarbeiter im ESE-Projekt. Das 'Projekt Empirische Sozialforschung über Entwicklungsländer (ESE) ist ein Forschungs- und Datensammlungsprojekt, welches vom Zentralarchiv in Zusammenarbeit mit der Arbeitsstelle für Entwicklungsländerforschung der Universität zu Köln durchgeführt wird. Quantitativ-empirische Datensätze aus der Entwicklungsländerforschung werden gesammelt, aufbereitet, dokumentiert und vom Zentralarchiv für Sekundäranalysen bereitgestellt. Auf diese Weise wird im Archiv eine Spezialsammlung von Entwicklungsländerstudien aufgebaut, die einen leichten Datenzugang ermöglichen soll. Das ESE-Projekt wird von der Stiftung Volkswagenwerk gefördert.' Auf der Grundlage der durch dieses Projekt erarbeiteten Datenbasis wird 'für den Bereich der Kleinbetriebs- oder 'informal sector'- Forschung, in dem Befragungen von Kleinbetriebsinhabern seit den 70er Jahren eine bedeutende Rolle spielen, die Entwicklung eines standardisierten Erhebungsinstrumentariums in Form von Fragebogenmodulen als Mittel zur Verbesserung der Datenqualität und zur langfristigen Unterstützung vergleichender Analysen vorgeschlagen.' Der Beitrag berichtet über den Stand der Entwicklung dieses Instrumentariums. Der Fragebogen ist in die vier folgenden Hauptmodule gegliedert: (1) Basic Business Variables; (2) Socio-demographic Data; (3) Household Data; (4) Training and Occupation. (pmb

Influence of ecological optimized manufacturing on the production costs of C/C structures using CVI technology

Please click Additional Files below to see the full abstract. Please click Download on the upper right corner to see the presentation

Caspofungin for treatment of invasive aspergillosis in Germany: results of a pre-planned subanalysis of an international registry

<p>Abstract</p> <p>Background</p> <p>This study is a pre-planned country-specific subanalysis of results in Germany from a multinational multicenter registry to prospectively assess real-world experience with caspofungin administered for treatment of proven or probable invasive aspergillosis (IA).</p> <p>Methods</p> <p>Data from patients treated with caspofungin for a single episode of IA were collected. Effectiveness was determined by the local investigator as favorable (complete or partial response) or unfavorable (stable disease, failure or death) at the end of caspofungin therapy. Descriptive statistics with binomial exact confidence intervals were employed.</p> <p>Results</p> <p>Forty-two consecutive patients were identified in three German centers. Three patients (7%) had proven IA and 39/42 (93%) had probable IA (modified European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) criteria). Forty-one patients had pulmonary IA and one had tracheal IA. Caspofungin monotherapy was received by 36/42 patients (86%); of these, 26/36 (72%) received salvage therapy. A favorable response was observed in 29/42 patients (69%; 95% CI 53 to 82%); of these, 21/29 (72%) had a complete and 8/29 (28%) a partial response. Favorable response rate was 69% in patients with monotherapy (95% CI 52% to 84%; 25/36 patients), and 67% in patients receiving combination therapy (95% CI 22% to 96%; 4/6 patients). Favorable response rate in patients with first line therapy was 64% (95% CI 31% to 89%; 7/11 patients), and 73% in patients with second line therapy (95% CI 54% to 88%; 20/30 patients). No adverse events were reported. In total, 35/42 patients (83%; 95% CI 69 to 93%) survived seven days after completion of caspofungin therapy.</p> <p>Conclusions</p> <p>These real-life findings in Germany are consistent with the international findings from this registry and with findings from randomized studies.</p

Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole

Invasive fungal infections are frequent and often deadly complications in patients with malignant hematological diseases. Voriconazole is a third generation triazole antifungal with broad activity against most clinically relevant fungal pathogens. Clinical practice often deviates from insights gained from controlled randomized trials. We conducted a multi-centre survey to evaluate efficacy, safety, treatment indications and dosing of voriconazole outside clinical trials. Patients receiving voriconazole were documented via electronic data capturing. An analysis was conducted after submission of 100 episodes from September 2004 to November 2005. Voriconazole was administered for suspected or proven invasive fungal infection (IFI) (57%), as empirical treatment in patients with fever of unknown origin (21%) and secondary (19%) as well as primary (3%) prophylaxis of IFI. Investigators’ assessment of fungal infection often diverted from EORTC/MSG 2002 criteria. A favorable response was reported in 61.4% for suspected or proven IFI and 52.4% for empirical treatment. Mortality was 15%, 26.7% of which was attributable to IFI. Breakthrough fungal infections occurred in four (21.1%) patients with voriconazole as secondary prophylaxis. Toxicity and adverse events comprised elevated liver enzymes and visual disturbances. Although indications frequently deviated from clinical evidence and legal approval, voriconazole showed efficacy and safety, comparable to major controlled clinical trials. Data from this survey demonstrate the difficulty of putting drugs to their approved use in IFI

Caspofungin Use in Daily Clinical Practice for Treatment of Invasive Aspergillosis: Results of a Prospective Observational Registry

<p>Abstract</p> <p>Background</p> <p>A prospective observational registry assessed real world experience with caspofungin monotherapy or combination therapy for the initial or salvage treatment of proven or probable invasive aspergillosis (IA).</p> <p>Methods</p> <p>Data were collected from April 2006 to September 2007 for patients treated with caspofungin for a single episode of IA. Clinical effectiveness was categorized as favorable (complete or partial) or unfavorable (stable disease or failure) at the end of caspofungin therapy (EOCT).</p> <p>Results</p> <p>Consecutive patients (n = 103) with proven or probable IA (per EORTC/MSG criteria) were identified from 11 countries. Malignancy (76.7%), neutropenia (64.1%), allogeneic hematopoietic stem cell transplantation (HSCT, 22.3%), solid organ transplantation (8.7%), autologous HSCT (4.9%), and HIV/AIDS (2.9%) were the most common underlying conditions. Most patients (84.5%) had pulmonary IA. <it>Aspergillus fumigatus </it>was the most frequently isolated species. The majority of patients received caspofungin monotherapy (82.5%) primarily as salvage therapy (82.4%). The main reason for switching to salvage therapy was clinical failure of the first-line therapy (69%). A favorable response at EOCT was seen in 56.4% (57/101) of patients overall, including 56.5% (48/85) and 56.3% (9/16) of patients receiving caspofungin monotherapy and combination therapy, respectively. Favorable response rates in clinically relevant subgroups were: malignancy, 51.9% (41/79); allogeneic HSCT, 56.5% (13/23); and neutropenia at time of hospitalization, 53.0% (35/66). There was a 72.3% (73/101) survival at 7 days after EOCT. Serious adverse events related to caspofungin were reported in 4 cases (3.9%); 3 patients (2.9%) discontinued treatment due to an adverse event related to caspofungin.</p> <p>Conclusions</p> <p>Caspofungin was both effective and well tolerated among high-risk patient groups such as those with neutropenia and active malignancies.</p

A Validated Preclinical Animal Model for Primary Bone Tumor Research

Funding for this study was provided by the German Research Foundation (Grant DFG WA 3606/1-1 to F. Wagner and Grant HO 5056/1-1 to B.M. Holzapfel), the Australian Research Council (Future Fellowship Program) and the Technical University Munich Hans Fischer Senior Fellowship (D.W. Hutmacher), and a Research Fellowship from the National Health and Medical Research Council (#1044091 to J.-P. Lévesque

Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance

OBJECTIVE: Chemoresistance is a critical feature of advanced ovarian cancer with only 30% of patients surviving longer than 5 years. We have previously shown that four kallikrein-related (KLK) peptidases, KLK4, KLK5, KLK6 and KLK7 (KLK4-7), are implicated in peritoneal invasion and tumour growth, but underlying mechanisms were not identified. We also reported that KLK7 overexpression confers chemoresistance to paclitaxel, and cell survival via integrins. In this study, we further explored the functional consequenses of overexpression of all four KLKs (KLK4-7) simultaneously in the ovarian cancer cell line, OV-MZ-6, and its impact on integrin expression and signalling, cell adhesion and survival as contributors to chemoresistance and metastatic progression. METHODS: Quantitative gene and protein expression analyses, confocal microscopy, cell adhesion and chemosensitivity assays were performed. RESULTS: Expression of α5β1/αvβ3 integrins was downregulated upon combined stable KLK4-7 overexpression in OV-MZ-6 cells. Accordingly, the adhesion of these cells to vitronectin and fibronectin, the extracellular matrix binding proteins of α5β1/αvβ3 integrins and two predominant proteins of the peritoneal matrix, was decreased. KLK4-7-transfected cells were more resistant to paclitaxel (10-100 nmol/L: 38-54%), but not to carboplatin, which was associated with decreased apoptotic stimuli. However, the KLK4-7-induced paclitaxel resistance was not blocked by the MEK1/2 inhibitor, U0126. CONCLUSIONS: This study demonstrates that combined KLK4-7 expression by ovarian cancer cells promotes reduced integrin expression with consequently less cell-matrix attachment, and insensitivity to paclitaxel mediated by complex integrin and MAPK independent interactions, indicative of a malignant phenotype and disease progression suggesting a role for these KLKs in this process